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ABSTRACT
Background    At the end of 2016, robot-assisted tho-
racoscopic surgery (RATS) was still not covered by 
Japanese national health insurance. Therefore, few in-
stitutions in Japan perform RATS and even fewer have 
reported procedures as they occurred earlier. So, we de-
cided to focus on the initial results of RATS for primary 
lung cancer. 
Methods    We retrospectively reviewed 44 patients 
who underwent RATS for primary lung cancer from 
January 2011 to August 2016. After mastering the initial 
procedure, we introduced a completely portal robotic 
pulmonary resection procedure using a carbon dioxide 
insufflation system. Cases were divided into 2 groups: 
the early period (20 cases) and the later period (24 cas-
es).
Results    There was no case of conversion to video-as-
sisted thoracoscopic surgery or thoracotomy. In the 44 
cases of primary lung cancer, median operating time 
was 239.5 min, console time was 179 min, blood loss 
was 10 mL, drainage period was 2 days, morbidity of 
Grade 2 or more (Clavien-Dindo classification) was 
18.2%, morbidity of Grade 3 or more was only 4.6%, 
and there was no 30-day mortality. Median operating 
and console times were significantly shorter in the later 
period (215 min and 159.5 min, respectively) than in 
the initial period (300.5 min and 228 min, respectively). 
Median blood loss was significantly lower in the later 
period (5 mL) than in the initial period (50 mL). Five-
year overall and disease-free survival rates were 100% 
and 88.9%, respectively.
Conclusion    RATS for primary lung cancer is feasible 
and safe, has a faster learning curve, and provides satis-
factory. Studies with longer follow-ups and larger num-
bers of cases are necessary. 
Key words    initial results; primary lung cancer; robotic 
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Robot-assisted thoracoscopic surgery (RATS) for lung 
cancer was first reported by Melfi et al. in 2002.1 Since 
then, RATS for lung cancer has become widely adopt-
ed, centering in Europe and North America. In Japan, 
the Pharmaceutical Affairs Council of the Ministry of 
Health, Labour and Welfare approved the da Vinci S 
Surgical System (Intuitive Surgical, Sunnyvale, CA) in 
November 2009, followed by the da Vinci Si Surgical 
System (Intuitive Surgical) in October 2012. In 2010, 
Suda et al.2 performed the first case of RATS lobectomy 
for lung cancer in Japan. We began performing RATS 
for general thoracic surgery (lung cancer and mediasti-
nal disease) in January 2011, and reported on the pro-
cedures in 2012.3 Furthermore, the initial results of 60 
cases of RATS for lung cancer in 9 institutions in Japan 
were reported in 2014.4 However, at the end of 2016, 
RATS was still not covered by Japanese national health 
insurance. Therefore, few institutions in Japan perform 
RATS, and even fewer have reported the initial results. 
Here, we report the initial results of RATS for prima-
ry lung cancer at a single institution, and compare the 
perioperative outcomes of the early period with those of 
the later period.
SUBJECTS AND METHODS
Patients and data collection
We performed RATS for 45 lung cancer patients using 
the da Vinci S or Si Surgical System from January 2011 
to August 2016 at our hospital. However, one case was 
diagnosed as metastatic lung tumor from ovarian cancer, 
histologically. Thus, we retrospectively analyzed 44 pa-
tients who underwent RATS for primary lung cancer.
 There were 17 men and 27 women with a median 
age of 70.0 years (range, 39–83 years). According to the 
7th edition of the TNM classification,5 all cases were 
clinical N0, and 43 cases were clinical stage I. One case 
was clinical stage II because of T3 classification. How-
ever, the number of cases of pathologic stage I decreased 
to 38. The most common histologic type was adenocar-
cinoma (40 cases). Standard lobectomy was performed 
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Fig. 1. Standard trocar placement (A) and the photo of docking with the robotic arms (B) for completely portal robotic pulmonary resec-
tion with 4 arms using a carbon dioxide insufflation system.
in 42 cases (95%), comprised of 20 right upper lobecto-
my (including 1 case of bronchoplasty), 6 right middle 
lobectomy, 4 right lower lobectomy, 7 left upper lobec-
tomy, and 5 left lower lobectomy. Segmentectomy was 
performed in 2 cases, comprised of including the left 
upper segmentectomy and left basal segmentectomy.
 Patients who underwent RATS for primary lung 
cancer were divided into 2 groups: the early period 
(before the 20th case) and the later period (after the 
21st case). The study protocol was approved by the In-
stitutional Review Board of Tottori University Faculty 
of Medicine (Approval No. 1528), and informed con-
sent was obtained from each patient before operation. 
Perioperative outcomes and survival data were analyzed. 
Morbidity, defined as postoperative complication within 
30 days after surgery, was classified according to the 
Clavien-Dindo classification system.6
Operative indication and surgical technique
The indications for RATS for primary lung cancer were 
the same as stage I non-small-cell lung cancer in accor-
dance with video-assisted thoracoscopic surgery (VATS) 
lobectomy and segmentectomy. 
 Our robotic operative technique has been described 
previously.3 First port was placed in the seventh or 
eighth intercostal space along the mid-axillary line for 
the camera (12 mm, 30° angled down scope). The other 
8-mm da Vinci trocars were placed in the fifth intercos-
tal space along the anterior-axillary line (for the second 
arm), seventh intercostal space along the posterior-ax-
illary line (for the third arm), and seventh intercostal 
space on the posterior side of the tip of the scapula (for 
the fourth arm). More than 8 cm of distance between 
each robotic port was required. A utility port for the as-
sistant surgeon was placed in the fifth intercostal space 
along the anterior-axillary line or used the same incision 
for the fourth arm. We performed RATS using 3 arms 
initially, and introduced the fourth arm from the 11th 
case. Furthermore, we introduced a completely portal 
robotic pulmonary resection (CPRL) technique7 using a 
CO2 insufflation system with pressure setting at 5 to 10 
mmHg from the 28th case (Fig. 1). 
Statistical analyses
Comparisons between groups were performed us-
ing the chi-squared test for categorical data, and the 
Mann-Whitney U test for nonparametric data. Survival 
was calculated using the Kaplan-Meier method. All 
statistical analyses were performed using StatView 5.0J 
(SAS Institute, Cary, NC). A P value of 0.05 was consid-
ered significant. 
RESULTS
Perioperative outcomes of all patients who under-
went RATS for primary lung cancer
There was no case of conversion to VATS or open 
thoracotomy. Median operating time was 239.5 min, 
console time was 179 min, blood loss was 10 mL, drain-
age period was 2 days, morbidity of Grade 2 or more 
(Clavien-Dindo classification) was 8 cases (18.2%), mor-
bidity of Grade 3 or more was 2 cases (4.5%), comprised 
of chylothorax and cholecystitis. There was no 30-day 
mortality. 
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Table 1. Patient characteristics between the early period 
and the later period
Early period Later period P value
No. of cases 20 24
Gender 0.87
Male 8 9
Female 12 15
Age, median (y) 74 (39–83) 66.5 (59–80) 0.47
Clinical stage 0.65
IA 13 15
IB 7 8
IIB 0 1
Histology 0.85
Adenocarcinoma 18 22
Squamous cell carcinoma 2 2
Pathologic stage 0.81
IA 11 15
IB 6 6
IIA 2 1
IIB 1 1
IIIA 0 1
Surgical procedure 0.89
Lobectomy 19 23
(including bronchoplasty 1)
Segmentectomy 1 1
No., number; y, year(s).
Table 2. Perioperative outcomes between the early period and the later period
Early period Later period P value 
No. of cases 20 24
Operating time, median (min) 300.5 (208–555) 215 (120–304) 0.0001
Console time, median (min) 228 (157–400) 159.5 (72–221) < 0.0001
Blood loss, median (mL) 50 (5–200) 5 (5–350) 0.37
Drainage period, median (d) 2 (1–4) 2 (2–10) 0.73
Morbidity* (≥ G2), (%) 3 (15.0) 5 (20.8) 0.62
Respiratory morbidity* (≥ G3), (%) 0 (0) 1 (4.2) 0.36
*Clavien-Dindo classification. No., number.
Comparison of perioperative outcomes between 
the early period and the later period of patients 
who underwent RATS for primary lung cancer
Table 1 shows the characteristics between the early 
period (20 cases) and the later period (24 cases) of the 
patients who underwent RATS for primary lung cancer. 
There were no significant differences in gender, age, 
clinical stage, histology, pathologic stage, and surgical 
procedure between periods. Table 2 shows the periop-
erative outcomes between the early period and the later 
period. Operating time was significantly shorter in the 
later period (median, 215 min) than in the early period 
(median, 300.5 min) (P = 0.0001). Console time also 
was significantly shorter in the later period (median, 
159.5 min) than in the early period (median, 228 min) (P 
< 0.0001). Moreover, blood loss was significantly lower 
in the later period (median, 5 mL) than in the early peri-
od (median, 50 mL) (P = 0.008). However, there were no 
significant differences in drainage period, morbidity of 
Grade 2 or more and respiratory morbidity of Grade 3 or 
more between periods. 
Survival of patients who underwent RATS for pri-
mary lung cancer
At a median follow-up of 34.5 months (range, 1–67 
months), all 44 patients who underwent RATS were 
alive, while 4 patients experienced recurrence. Recur-
rence site was pleural and pulmonary metastasis in 1 
case, pulmonary metastasis in 1, pleural and bone me-
tastasis in 1, and trachea-bronchus recurrence in 1 (bron-
choplastic right upper lobectomy, 65-month dis-
ease-free period). Five-year overall and disease-free 
survival rates were 100% and 88.9%, respectively 
(Fig. 2).
DISCUSSION
The main reasons that RATS has not become 
widely adopted in Japan seem to be problems with 
national health insurance and cost.4 Additionally, 
there are some risk-benefit problems characteristic 
of the thoracic organs in the general thoracic sur-
gery field: i) numerous great vessels with abundant 
blood flow are present in the thoracic cavity; ii) the 
target area is wide; iii) the main procedure is resec-
tion, and reconstruction procedures are limited; iv) 
only limited institutions have introduced complete 
thoracoscopic surgery; and v) the learning curve is 
slower than that in other fields.8
 In this study, regarding perioperative outcomes, 
there was no case of conversion to VATS or open 
thoracotomy, morbidity of Grade 3 or more was 
only 4.6%, and no 30-day mortality. The learning 
curve was 20 cases.
 RATS for lung cancer was introduced with low 
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for lung cancer using 4 arms and CO2 insufflation is 
effective in terms of perioperative outcomes, including 
operating time and rates of conversion, mortality, and 
morbidity. We believe that CPRL with CO2 insufflation 
is useful to widen the working space of robotic forceps. 
Furthermore, Nasir et al.17 referred to the possibility that 
CPRL with CO2 insufflation might prevent tissue desic-
cation and further inflammation in the chest. As for CO2 
pressure, previous studies reported that RATS should be 
performed using 10 mmHg or less.7, 16 Moreover, Wolfer 
et al.18 proposed that low-pressure (< 10 mmHg) insuf-
flation is a safe adjunct to the conduct of routine thora-
coscopic surgical procedures, because central venous 
pressure significantly increases at 14 mmHg. Therefore, 
we introduced CPRL using a CO2 insufflation system 
with pressure setting at 5 to 10 mmHg. There is a pos-
sibility that CPRL with CO2 insufflation influenced the 
significantly lower blood loss in the later period on our 
study.
 As for the long-term survival after RATS, there are 
few reports.19, 20 Park et al.19 reported a multicenter study 
involving 325 patients, in which the 5-year survival rate 
in all patients was 80% (stage IA, 91%; stage IB, 88%; 
stage II, 49%). Recently, Yang et al.20 reported the long-
term survival of 172 patients who underwent RATS 
lobectomy for clinical stage I lung cancer, in which the 
5-year overall and disease-free survival rates were 77.6% 
and 72.7%, respectively. Our results were more favorable 
in spite of small series and short follow up time.
 We performed RATS bronchoplastic right upper 
lobectomy as it was reported previously.21 For sleeve 
or bronchoplastic lobectomy, some reports also have 
described one of the great advantage of RATS.22, 23 Be-
sides this, some reports have described the usefulness 
of RATS for lymph node dissection.24, 25 However, re-
garding its usefulness and advantages, almost all reports 
cited so far included limited numbers of cases, were ret-
rospective studies, and/or conducted propensity-matched 
analyses, and there are very few prospective randomized 
trials. Recently, it was reported that a prospective, ran-
domized, multicenter trial (NCT02804893) to compare 
the complications and conversion rates between RATS 
and VATS approaches for stage I and II lung cancer have 
just begun.26 We will expect the beneficial results of this 
randomized trial.
 In the present study, of course there are several 
limitations: single-institution, nonrandomized, retro-
spectively analyzed cohort of patients, the most obvious 
being a selection bias. This study also did not analyze 
the influence of CPRL with CO2 insufflation. However, 
when considering the current state that RATS is not cov-
ered by Japanese national health insurance, we believe 
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Fig. 2. Survival curves of patients who underwent robotic surgery 
for primary lung cancer.
rates of morbidity (6.7%–43.8%) and mortality (0%–0.4%).4, 
7, 9–11 In this study, morbidity and mortality rates were 
18.2% and 0%, respectively, demonstrating that RATS 
for lung cancer was safely introduced at our institution. 
In a previous study, Kent et al.10 compared the periop-
erative outcomes between RATS, VATS, and open 
thoracotomy procedures for lung cancer using propen-
sity-matched analysis based on data from the state inpa-
tient database. They reported that RATS was associated 
with significant reductions in mortality, length of hospi-
tal stay, and overall complication rates when compared 
with open thoracotomy, but that none of these differenc-
es were significant when compared with VATS. Paul et 
al.,12 using a nationwide inpatient sample, reported that 
RATS lobectomy was associated with higher rates of 
intraoperative injury and bleeding compared with VATS 
lobectomy. On the other hand, Farivar et al.,11 using 
comparative analysis based on data from the Society of 
Thoracic Surgeons national database, suggested the po-
tential benefits of RATS relative to VATS and open tho-
racotomy for lung cancer, particularly reduced length of 
hospital stay, mortality, and postoperative blood transfu-
sion. Therefore, the evidence is still inconclusive wheth-
er RATS is more useful than VATS for lung cancer 
with regard to perioperative outcomes. Previous studies 
demonstrated that operating time of RATS for lung 
cancer was longer than that of VATS for lung cancer.13, 14 
However, Veronesi15 reported that the learning curve of 
RATS lobectomy (number of operations required, 6–20) 
was shorter than that of VATS lobectomy (number of 
operations required, 25–50). In our study, operating and 
console times were significantly shorter after around 
20cases. Thus, our data seem to support Veronesi’s idea.
 Regarding CPRL, Melfi et al.16 reported that RATS 
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there is a significance of this retrospective study.
 In conclusion, RATS for lung cancer is feasible and 
safe, has a faster learning curve, and provides satisfacto-
ry initial results. However, studies with longer follow-up 
and larger numbers of cases are necessary. Prospective 
studies showing favorable result of RATS are mandatory 
for coverage by Japanese national health insurance.
The authors declare no conflict of interest.
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